தேசிய புற்றுநோய் நிறுவனம் கண்காணிப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from தேசிய புற்றுநோய் நிறுவனம் கண்காணிப்பு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In தேசிய புற்றுநோய் நிறுவனம் கண்காணிப்பு Today - Breaking & Trending Today

Transcenta Announces Orphan Drug Designation Granted to TST001 for Treatment of Gastric and Gastroesophageal Junction

Transcenta Announces Orphan Drug Designation Granted to TST001 for Treatment of Gastric and Gastroesophageal Junction
News provided by
Share this article
Share this article
SUZHOU, China, July 28, 2021 /PRNewswire/ Transcenta Holding Limited ( Transcenta ), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to TST001, its anti-Claudin18.2 monoclonal antibody currently in Phase I clinical trial, for the treatment of patients with gastric cancer or gastroesophageal junction (GC/GEJ). According to preclinical and clinical data, TST001 displayed potent anti-tumor activities in tumor model of gastric cancer or patient of gastric cancer expressing Claudin18.2. ....

United States , Los Angeles , Michael Shi , Clinical Development Centers , Transcenta Holding , Drug Administration , Product Development Center , Translational Research Center , Prnewswire Transcenta Holding Limited , National Cancer Institute Surveillance , End Results Program , Business Development , Transcenta Immune Tolerance Breaking Technology , Holding Limited , Orphan Drug Designation , National Cancer Institute , Drug Designation , Immune Tolerance Breaking Technology , Manufacturing Facility , External Partnering Center , ஒன்றுபட்டது மாநிலங்களில் , லாஸ் ஏஞ்சல்ஸ் , மைக்கேல் ஷி , மருத்துவ வளர்ச்சி மையங்கள் , ப்ராடக்ட் வளர்ச்சி மையம் , மொழிபெயர்ப்பு ஆராய்ச்சி மையம் ,

Universal health care benefited colon cancer survival

Universal health care benefited colon cancer survival
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.

United States , Craigd Shriver , Health System , Department Of Defense Automated Central Tumor Registry , National Cancer Institute , Department Of Defense , Us Military Health System , National Cancer Institute Surveillance , American Association For Cancer Research , Johnp Murtha Cancer Center Research Program , Uniformed Services University Of The Health Sciences , Us Army , National Guard , Cancer Epidemiology , American Association , Murtha Cancer Center Research Program , Uniformed Services University , Health Sciences , Military Health System , Automated Central Tumor Registry , End Results , Cancer Center Research Program , Military Medicine , National Cancer , ஒன்றுபட்டது மாநிலங்களில் , ஆரோக்கியம் அமைப்பு ,

Charles Grodin's Death From Multiple Myeloma

A look at the beloved actor's highly treatable but rarely curable disease ....

United States , David Letterman , Johnny Carson , Mia Farrow , Kathy Griffin , Charles Grodin , Steve Martin , National Cancer Institute Surveillance , End Results Program , Actor Charles Grodin , Heartbreak Kid , Can Wait , Night With David , Tonight Show Starring Johnny Carson , Miss Piggy , National Cancer Institute , Multiple Myeloma , Monoclonal Gammopathy Of Undetermined Significance , ஒன்றுபட்டது மாநிலங்களில் , டேவிட் லெட்டர்மேன் , ஜானி கார்சன் , மியா ஃப்யாரோ , கத்தி கிரிஃபின் , ஸ்டீவ் மார்டின் , தேசிய புற்றுநோய் நிறுவனம் கண்காணிப்பு , முடிவு முடிவுகள் ப்ரோக்ர்யாம் ,

Novartis Pharma AG: Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera

At final analysis, study showed clinically relevant improvement in median overall survival with a difference of 11.7 months between arms (Hazard ratio (HR): 0.84 with 95% CI: (0.60, 1.17) (p=0.30 ....

United States , Isabella Zinck , Samir Shah , Julie Masow , Thomas Hungerbuehler , Sloan Simpson , Rachel Levine , Nuclear Medicine Through Innovation , Novartis Company , Elsevier Inc , Novartis External Communications , Exchange Commission , National Cancer Institute Surveillance , National Research Council , Institute Of Medicine , National Academies , National Cancer Institute , End Results , Advanced Accelerator Applications , Prescribing Information , Accelerator Applications , Positron Emission Tomography , Single Photon Emission Computed Tomography , Midgut Neuroendocrine , New Englandj Med , Product Characteristics ,

Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera

Share this article
Share this article
EAST HANOVER, N.J., June 3, 2021 /PRNewswire/ Novartis today reported the final analysis from the NETTER-1 phase III study comparing treatment using Lutathera
® (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) plus 30 mg octreotide LAR to 60 mg of octreotide LAR in patients with midgut neuroendocrine tumors. The previously reported primary analysis of the trial demonstrated a statistically significant improvement in progression free survival (PFS) (HR: 0.18 , p 0.0001)
3. In the final analysis of overall survival, a secondary objective of the trial, treatment with Lutathera resulted in a clinically relevant prolongation in median overall survival of 11.7 months [48.0 months (95%CI: 37.4-55.2) compared to the control arm (36.3 months (95%CI: 25.9-51.7)] ....

United States , Isabella Zinck , Samir Shah , Julie Masow , Thomas Hungerbuehler , Sloan Simpson , Rachel Levine , Prnewswire Novartis , Nuclear Medicine Through Innovation , Virtual Scientific Program , Novartis Company , Elsevier Inc , Novartis External Communications , Exchange Commission , National Cancer Institute Surveillance , National Research Council , Institute Of Medicine , Novartis Pharmaceuticals Corporation , National Academies , Scientific Program , National Cancer Institute , End Results , Advanced Accelerator Applications , Accelerator Applications , Positron Emission Tomography , Single Photon Emission Computed Tomography ,